CPT code 87324 represents an immunoassay laboratory test to detect one or more toxins produced by Clostridium difficile, commonly used to evaluate patients with suspected C. difficile infection. Nationally, this code is central to laboratory confirmation of toxin-mediated disease and affects inpatient and outpatient testing workflows, infection control decisions, and laboratory reimbursement processes.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how 87324 is described clinically, typical sites of service, common payer coverage considerations, and the payer mix used in benchmarking. The publication outlines common modifiers associated with laboratory billing and highlights areas where policy updates or clinical practice patterns can influence utilization. Clinical context explains the role of toxin immunoassays versus other diagnostic modalities for Clostridium difficile.

The report supplies practical benchmarking and policy-oriented context for laboratory managers, billing professionals, and healthcare administrators seeking to understand coding, payer approaches, and where to look for documentation or billing variances. Data not available in the input is explicitly noted where applicable.